We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NMTC Stock Gains as FDA Clears OneRF System for Facial Pain Treatment
Read MoreHide Full Article
Key Takeaways
NMTC gained FDA clearance for its OneRF Trigeminal Nerve Ablation System for facial pain.
The system uses multi-contact RF probe tech for precise, temperature-controlled ablation.
NMTC plans a limited commercial launch in Q4 2025, eyeing revenue growth opportunities.
NeuroOne Medical Technologies Corporation (NMTC - Free Report) recently received FDA 510(k) clearance for its OneRF Trigeminal Nerve Ablation System, a minimally invasive solution for treating severe facial pain. The system delivers targeted radiofrequency energy to ablate trigeminal nerve fibers, offering an alternative to traditional medications or invasive surgical procedures. NMTC now targets a limited commercial launch in the fourth quarter of 2025.
The OneRF platform leverages proprietary multi-contact RF probe technology, allowing precise localization and tailored ablation under temperature-controlled conditions. This innovation aims to improve patient safety, reduce procedural time, and expand NMTC’s footprint in pain management. The FDA clearance also opens doors for future applications across other neurological and pain-related therapies, positioning the company for potential revenue growth as early as late 2025.
Likely Trend of NMTC Stock Following the News
Following the announcement yesterday, the company's shares have gained 7% in today’s pre-market trading. Shares have gained 0.5% in the year-to-date period compared with the industry’s 1% growth. The S&P 500 has gained 9.6% in the same time frame.
The FDA clearance is a significant growth catalyst for NMTC, as it expands the company’s OneRF platform into the large pain management market. By offering a minimally invasive alternative to invasive surgeries, the system strengthens NMTC’s commercial pipeline and creates near-term revenue potential with a limited launch in late 2025. Longer term, the clearance validates the versatility of the OneRF platform, supporting expansion into broader neurological and pain therapy applications, which could accelerate adoption, attract strategic partnerships, and diversify revenue streams.
NMTC currently has a market capitalization of $40.9 million.
Image Source: Zacks Investment Research
More on NeuroOne's OneRF Platform
Trigeminal neuralgia is a chronic pain condition that impacts a significant number of people in the United States each year. The disorder arises from the trigeminal nerve, the primary sensory nerve of the face, and is associated with episodes of intense, debilitating pain. Traditional treatment options have typically centered on medications or invasive surgical approaches such as microvascular decompression, radiosurgery, and other percutaneous procedures, each carrying its own limitations and risks.
NeuroOne’s newly cleared OneRF Trigeminal Nerve Ablation System provides a minimally invasive alternative designed to interrupt pain signaling at its source. The system delivers targeted radiofrequency energy to ablate trigeminal nerve fibers and features a multi-contact RF probe that can both localize and ablate nerve tissue using the same instrument. With temperature-controlled functionality, the system enhances precision and safety while potentially reducing procedure time and improving overall patient comfort compared to conventional approaches.
The FDA clearance for this indication builds on the broader OneRF technology platform, which is already being applied in brain ablation procedures. By extending its use to facial pain, NeuroOne is taking its first step into pain management therapies. The platform’s adaptability offers further opportunities in additional areas such as lower back pain, while ongoing collaborations with existing users and potential strategic partners may support its clinical and commercial adoption.
Favorable Industry Prospects for NMTC
Per a report by Straits Research, the global trigeminal neuralgia treatment market size was valued at $255.09 million in 2024 and is anticipated to reach $392.34 million by 2033, exhibiting a CAGR of 4.9% during the forecast period.
The market is primarily boosted by the surging incidence of trigeminal neuralgia worldwide. Additionally, the surge in the geriatric population is further increasing the burden of this disease, which is anticipated to expedite the market expansion.
NMTC’s Zacks Rank & Key Picks
Currently, NMTC carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have announced quarterly results are Medpace Holdings, Inc. (MEDP - Free Report) , West Pharmaceutical Services, Inc. (WST - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
Medpace Holdings, sporting a Zacks Rank of 1 (Strong Buy), reported second-quarter 2025 EPS of $3.10, beating the Zacks Consensus Estimate by 3.3%. Revenues of $603.3 million outpaced the consensus mark by 11.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.9%.
West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, beating the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1.
West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2 (Buy).
Boston Scientific has a long-term estimated growth rate of 14%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
NMTC Stock Gains as FDA Clears OneRF System for Facial Pain Treatment
Key Takeaways
NeuroOne Medical Technologies Corporation (NMTC - Free Report) recently received FDA 510(k) clearance for its OneRF Trigeminal Nerve Ablation System, a minimally invasive solution for treating severe facial pain. The system delivers targeted radiofrequency energy to ablate trigeminal nerve fibers, offering an alternative to traditional medications or invasive surgical procedures. NMTC now targets a limited commercial launch in the fourth quarter of 2025.
The OneRF platform leverages proprietary multi-contact RF probe technology, allowing precise localization and tailored ablation under temperature-controlled conditions. This innovation aims to improve patient safety, reduce procedural time, and expand NMTC’s footprint in pain management. The FDA clearance also opens doors for future applications across other neurological and pain-related therapies, positioning the company for potential revenue growth as early as late 2025.
Likely Trend of NMTC Stock Following the News
Following the announcement yesterday, the company's shares have gained 7% in today’s pre-market trading. Shares have gained 0.5% in the year-to-date period compared with the industry’s 1% growth. The S&P 500 has gained 9.6% in the same time frame.
The FDA clearance is a significant growth catalyst for NMTC, as it expands the company’s OneRF platform into the large pain management market. By offering a minimally invasive alternative to invasive surgeries, the system strengthens NMTC’s commercial pipeline and creates near-term revenue potential with a limited launch in late 2025. Longer term, the clearance validates the versatility of the OneRF platform, supporting expansion into broader neurological and pain therapy applications, which could accelerate adoption, attract strategic partnerships, and diversify revenue streams.
NMTC currently has a market capitalization of $40.9 million.
Image Source: Zacks Investment Research
More on NeuroOne's OneRF Platform
Trigeminal neuralgia is a chronic pain condition that impacts a significant number of people in the United States each year. The disorder arises from the trigeminal nerve, the primary sensory nerve of the face, and is associated with episodes of intense, debilitating pain. Traditional treatment options have typically centered on medications or invasive surgical approaches such as microvascular decompression, radiosurgery, and other percutaneous procedures, each carrying its own limitations and risks.
NeuroOne’s newly cleared OneRF Trigeminal Nerve Ablation System provides a minimally invasive alternative designed to interrupt pain signaling at its source. The system delivers targeted radiofrequency energy to ablate trigeminal nerve fibers and features a multi-contact RF probe that can both localize and ablate nerve tissue using the same instrument. With temperature-controlled functionality, the system enhances precision and safety while potentially reducing procedure time and improving overall patient comfort compared to conventional approaches.
The FDA clearance for this indication builds on the broader OneRF technology platform, which is already being applied in brain ablation procedures. By extending its use to facial pain, NeuroOne is taking its first step into pain management therapies. The platform’s adaptability offers further opportunities in additional areas such as lower back pain, while ongoing collaborations with existing users and potential strategic partners may support its clinical and commercial adoption.
Favorable Industry Prospects for NMTC
Per a report by Straits Research, the global trigeminal neuralgia treatment market size was valued at $255.09 million in 2024 and is anticipated to reach $392.34 million by 2033, exhibiting a CAGR of 4.9% during the forecast period.
The market is primarily boosted by the surging incidence of trigeminal neuralgia worldwide. Additionally, the surge in the geriatric population is further increasing the burden of this disease, which is anticipated to expedite the market expansion.
NMTC’s Zacks Rank & Key Picks
Currently, NMTC carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have announced quarterly results are Medpace Holdings, Inc. (MEDP - Free Report) , West Pharmaceutical Services, Inc. (WST - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
Medpace Holdings, sporting a Zacks Rank of 1 (Strong Buy), reported second-quarter 2025 EPS of $3.10, beating the Zacks Consensus Estimate by 3.3%. Revenues of $603.3 million outpaced the consensus mark by 11.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.9%.
West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, beating the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1.
West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2 (Buy).
Boston Scientific has a long-term estimated growth rate of 14%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%.